In a significant move for the field of synthetic biology, Beijing Tsingke Biotech Co., Ltd. and iGeneTech Bioscience Co., Ltd. have entered into a strategic partnership. This collaboration is designed to leverage the strengths of both organizations, ultimately enhancing innovation, accelerating product development, and broadening market access.
Transforming Synthetic Biology
Synthetic biology is quickly becoming a pivotal area of scientific inquiry, boasting applications that span precision medicine, bio-breeding, and gene editing. Central to these revolutionary advancements are high-throughput and column-based synthesis technologies, which both Tsingke Biotech and iGeneTech are poised to refine and expand.
Tsingke Biotech stands out as a leader in the gene synthesis landscape. The company has established a fully integrated industrial chain that encompasses raw materials, specialized equipment, innovative process design, and cutting-edge AI and digital technologies. Their offerings are known for scalability, standardization, and stability. The technology, which includes column synthesis and a smart factory-driven production system, facilitates a range of outputs from small laboratory-scale production (2nmol) to large industrial synthesis (12mmol).
Synergistic Technologies
On the flip side, iGeneTech brings its proprietary Ignite3.0 high-throughput synthesis platform into the partnership. This advanced platform can efficiently process oligo pools that range from 4,000 to 650,000 in size, achieving synthesis lengths of up to 200 nucleotides with error rates as low as 0.2%. Such capabilities address critical challenges in throughput, speed, and cost, making it a valuable asset for the collaboration.
Mr. Shijin Ma, CEO of Tsingke Biotech, expressed enthusiasm for the partnership, stating, “We are excited to partner with iGeneTech, whose expertise in gene capture and next-generation sequencing technology enhances our strengths in gene synthesis. This partnership will speed up the translation of technological innovations into real-world applications, helping drive the industry forward.”
A Vision for the Future
Mr. Wanshi Cai, CEO of iGeneTech, also highlighted the significance of this collaboration, noting, “Tsingke Biotech’s integrated industrial chain and leadership in gene synthesis will be crucial in supporting our continued growth. Together, we will push the boundaries of synthetic biology and its potential across various industries.”
Both companies are dedicated to creating an integrated system that spans the entire journey from synthesis to application. Their focus will be on innovation, sustainability, and precision, aiming to meet the demands of an ever-evolving market.
Pioneering Gene Synthesis
Tsingke Biotech’s mission is ambitious: to build “the world’s great gene factory.” By merging proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech offers efficient and high-quality gene synthesis services. Their innovations serve a wide range of industries, including biopharma, agriculture, food production, and environmental sciences.
Meanwhile, iGeneTech specializes in gene capture technologies and holds multiple patents in NGS probe hybridization, multiplex PCR, and high-throughput DNA synthesis. Their capabilities in high-quality oligo pool synthesis enable the creation of precise and uniform sgRNA libraries, essential for gene-editing applications, ranging from genome-wide studies to specific target-gene investigations, as well as off-target detection.
The Path Ahead
As these two industry leaders join forces, the potential for breakthroughs in synthetic biology becomes increasingly tangible. Their combined expertise and technological capabilities position them to tackle some of the most pressing challenges in the field.
In summary, the partnership between Tsingke Biotech and iGeneTech marks a pivotal moment in the evolution of synthetic biology. Together, they are set to redefine the landscape of gene synthesis and its applications across various sectors.
Key Takeaways:
- Tsingke Biotech and iGeneTech have formed a strategic partnership to advance synthetic biology.
- Tsingke Biotech excels in gene synthesis with an integrated industrial chain.
- iGeneTech’s Ignite3.0 platform enhances high-throughput synthesis capabilities.
- The collaboration aims to foster innovation, sustainability, and precision in the field.
- Together, they will address challenges and expand the applications of synthetic biology.
This alliance not only enhances their competitive edge but also promises to contribute significantly to the future of life sciences.
Read more → www.finanznachrichten.de